Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
An Editor's opinion of the recent committee opinion of the American Society for Reproductive Medicine that the luteal phase deficiency as a clinical entity causing infertility has not been proven
J. H. Check1,2,*
1 Cooper Medical School of Rowan University, Department of Obstetrics and Gynecology
1 Division of Reproductive Endocrinology & Infertility, Camden, NJ
2 Cooper Institute for Reproductive Hormonal Disorders, P.C., Mt. Laurel, NJ (USA)
Clin. Exp. Obstet. Gynecol. 2016, 43(4), 479–483; https://doi.org/10.12891/ceog3328.2016
Published: 10 August 2016
Purpose: To present an opposing view to the recent conclusions reached by the Practice Committee of the American Society for Reproductive Medicine and a recent review of the role of progesterone in subfertility by Sonntag and Ludwig that there is no evidence to support using progesterone in the luteal phase as exclusive therapy. Materials and Methods: A large quasi randomized study not mentioned by either review is presented. Results: In this study published in 1989 when women with luteal phase deficiencies and subfertility were evaluated for follicular maturation, the majority seemed to form mature follicles. This majority group found far better with pregnancy outcome by taking exclusive progesterone in the luteal phase than follicle maturing drugs. A recent prospective series confirmed its beneficial effect. Conclusions: Physicians should not empirically treat with follicle maturing drugs but should use progesterone in the luteal phase, preferably in those women who seemingly create a mature follicle.
Luteal phase deficiencies
Follicle maturing drugs